Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 3/20 | 0.36 |
| ▸ | BACE1 | P56817 | 10/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PLA2G7 | Q13093 | 4/20 | 0.33 |
| ▸ | BACE2 | Q9Y5Z0 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8204909 | 1.00 | PGR (0.36) | PGRBACE1ARPLA2G7BACE2 | |
| SCHEMBL12174414 | 1.00 | PGR (0.36) | PGRBACE1ARPLA2G7BACE2 | |
| SCHEMBL13558872 | 0.87 | BACE1 (0.33) | BACE1BACE2 | |
| SCHEMBL7559867 | 0.87 | BACE1 (0.44) | PGRBACE1ARBACE2 | |
| SCHEMBL13054227 | 0.87 | BACE1 (0.44) | PGRBACE1ARBACE2 | |
| SCHEMBL12174164 | 0.87 | BACE1 (0.44) | PGRBACE1ARBACE2 | |
| SCHEMBL8211797 | 0.86 | BACE1 (0.40) | PGRBACE1ARBACE2 | |
| SCHEMBL7558496 | 0.86 | BACE1 (0.40) | PGRBACE1ARBACE2 | |
| SCHEMBL13054166 | 0.86 | PGR (0.39) | PGRBACE1ARBACE2 | |
| SCHEMBL7571041 | 0.86 | PGR (0.39) | PGRBACE1ARBACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8183252-B2 | Heterocyclic aspartyl protease inhibitors | SCHERING CORPORATION (US) | 2012-05-22 | — | — | US | disclosed |
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | SCHERING CORPORATION | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292203-A1 | HETEROCYCLIC ASPARTYL PROTEASE INHIBITORS | CHRM1, CHRM2, PRSS1 | PGR 1172/4885BACE1 8/4885AR 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.